Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2010

View Archived Issues

PK/PD modeling of siltuximab predicts clinically feasible dosing regimen

Nycomed claims novel phosphodiesterase 5 inhibitors

BFPT-2603 safe and efficacious in monkey model of allergic asthma

Ulipristal noninferior to levonorgestrel for emergency contraception

Denosumab shows therapeutic activity in giant-cell tumor of bone

NicOx discloses novel nitric oxide-releasing steroids

Eisai discovers novel JNK3 kinase inhibitors

Dual M3 antagonists/beta2-adrenoceptor agonists claimed by Argenta and AstraZeneca

Genta raises funds for advancement Genasense and tesetaxel

Isis earns milestone payment from Bristol-Myers for BMS-PCSK9Rx

MDS Foundation comments on NICE's decision against Vidaza

Summit claims novel upregulators of endogenous utrophin

Roche and Biogen place ocrelizumab rheumatoid arthritis program on hold

Auxilium launches Xiaflex in U.S. for treatment of Dupuytren's contracture

Genmab reports phase III results on zalutumumab in refractory head and neck cancer

Nabi and GSK close NicVAX option and license agreement

Novavax completes enrollment in pivotal H1N1 flu vaccine trial

XenoPort to focus on key later-stage product candidates

FDA approves NDA for Alza's Exalgo for pain management

Nektar Therapeutics presents phase II data on NKTR-102 in platinum-resistant ovarian cancer

ExonHit and bioMerieux terminate colon cancer collaboration

Advaxis confirms long-term stability ADXS11-001 cancer vaccine

Mologen's phase II IMPACT trial of MGN-1703 in cancer approved in Germany and Austria

FDA and EMA grant orphan drug status to ImmunoGen's IMGN-901 in MCC

New neuraminidase inhibitor CS-8958 shows promise in preclinical and clinical evaluation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...